These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 31026260)

  • 1. Vaccination with a chikungunya virus-like particle vaccine exacerbates disease in aged mice.
    Arévalo MT; Huang Y; Jones CA; Ross TM
    PLoS Negl Trop Dis; 2019 Apr; 13(4):e0007316. PubMed ID: 31026260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-Immunization With CHIKV VLP and DNA Vaccines Induces a Promising Humoral Response in Mice.
    Zhao Z; Deng Y; Niu P; Song J; Wang W; Du Y; Huang B; Wang W; Zhang L; Zhao P; Tan W
    Front Immunol; 2021; 12():655743. PubMed ID: 33868299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus.
    Kumar M; Sudeep AB; Arankalle VA
    Vaccine; 2012 Sep; 30(43):6142-9. PubMed ID: 22884660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial.
    Chen GL; Coates EE; Plummer SH; Carter CA; Berkowitz N; Conan-Cibotti M; Cox JH; Beck A; O'Callahan M; Andrews C; Gordon IJ; Larkin B; Lampley R; Kaltovich F; Gall J; Carlton K; Mendy J; Haney D; May J; Bray A; Bailer RT; Dowd KA; Brockett B; Gordon D; Koup RA; Schwartz R; Mascola JR; Graham BS; Pierson TC; Donastorg Y; Rosario N; Pape JW; Hoen B; Cabié A; Diaz C; Ledgerwood JE;
    JAMA; 2020 Apr; 323(14):1369-1377. PubMed ID: 32286643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and Characterization of Yeast Derived Chikungunya Virus Like Particles (CHIK-VLPs) and Its Evaluation as a Potential Vaccine Candidate.
    Saraswat S; Athmaram TN; Parida M; Agarwal A; Saha A; Dash PK
    PLoS Negl Trop Dis; 2016 Jul; 10(7):e0004782. PubMed ID: 27399001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomal Delivery of the RNA Genome of a Live-Attenuated Chikungunya Virus Vaccine Candidate Provides Local, but Not Systemic Protection After One Dose.
    Abeyratne E; Tharmarajah K; Freitas JR; Mostafavi H; Mahalingam S; Zaid A; Zaman M; Taylor A
    Front Immunol; 2020; 11():304. PubMed ID: 32194557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial.
    Folegatti PM; Harrison K; Preciado-Llanes L; Lopez FR; Bittaye M; Kim YC; Flaxman A; Bellamy D; Makinson R; Sheridan J; Azar SR; Campos RK; Tilley M; Tran N; Jenkin D; Poulton I; Lawrie A; Roberts R; Berrie E; Rossi SL; Hill A; Ewer KJ; Reyes-Sandoval A
    Nat Commun; 2021 Jul; 12(1):4636. PubMed ID: 34330906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel MVA vectored Chikungunya virus vaccine elicits protective immunity in mice.
    Weger-Lucarelli J; Chu H; Aliota MT; Partidos CD; Osorio JE
    PLoS Negl Trop Dis; 2014 Jul; 8(7):e2970. PubMed ID: 25058320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenoviral-Vectored Mayaro and Chikungunya Virus Vaccine Candidates Afford Partial Cross-Protection From Lethal Challenge in A129 Mouse Model.
    Campos RK; Preciado-Llanes L; Azar SR; Kim YC; Brandon O; López-Camacho C; Reyes-Sandoval A; Rossi SL
    Front Immunol; 2020; 11():591885. PubMed ID: 33224148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits.
    Metz SW; Martina BE; van den Doel P; Geertsema C; Osterhaus AD; Vlak JM; Pijlman GP
    Vaccine; 2013 Dec; 31(51):6092-6. PubMed ID: 24099875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A measles virus-based vaccine induces robust chikungunya virus-specific CD4
    Schmitz KS; Comvalius AD; Nieuwkoop NJ; Geers D; Weiskopf D; Ramsauer K; Sette A; Tschismarov R; de Vries RD; de Swart RL
    Vaccine; 2023 Oct; 41(43):6495-6504. PubMed ID: 37726181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Virus-Like Particle Vaccine Elicits Broad Neutralizing Antibody Responses in Humans to All Chikungunya Virus Genotypes.
    Goo L; Dowd KA; Lin TY; Mascola JR; Graham BS; Ledgerwood JE; Pierson TC
    J Infect Dis; 2016 Nov; 214(10):1487-1491. PubMed ID: 27655868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Humoral Immune Responses in Chikungunya Virus (CHIKV)-Infected Patients and Individuals Vaccinated With a Candidate CHIKV Vaccine.
    Henss L; Yue C; Von Rhein C; Tschismarov R; Lewis-Ximenez LL; Dölle A; Baylis SA; Schnierle BS
    J Infect Dis; 2020 Apr; 221(10):1713-1723. PubMed ID: 31828322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine-Induced Skewing of T Cell Responses Protects Against Chikungunya Virus Disease.
    Broeckel RM; Haese N; Ando T; Dmitriev I; Kreklywich CN; Powers J; Denton M; Smith P; Morrison TE; Heise M; DeFilippis V; Messaoudi I; Curiel DT; Streblow DN
    Front Immunol; 2019; 10():2563. PubMed ID: 31736977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.
    Harro CD; Pang YY; Roden RB; Hildesheim A; Wang Z; Reynolds MJ; Mast TC; Robinson R; Murphy BR; Karron RA; Dillner J; Schiller JT; Lowy DR
    J Natl Cancer Inst; 2001 Feb; 93(4):284-92. PubMed ID: 11181775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial.
    Reisinger EC; Tschismarov R; Beubler E; Wiedermann U; Firbas C; Loebermann M; Pfeiffer A; Muellner M; Tauber E; Ramsauer K
    Lancet; 2019 Dec; 392(10165):2718-2727. PubMed ID: 30409443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigenicity and immunogenicity of chikungunya virus-like particles from mosquito cells.
    Tsai SK; Hsu YL; Chiao DJ; Shu PY; Lin HT; Chang SF; Lin HC; Huang SH; Wang CH; Hsiung CC; Lin CC; Wu TY; Kuo SC
    Appl Microbiol Biotechnol; 2023 Jan; 107(1):219-232. PubMed ID: 36434113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective chikungunya virus-like particle vaccine produced in insect cells.
    Metz SW; Gardner J; Geertsema C; Le TT; Goh L; Vlak JM; Suhrbier A; Pijlman GP
    PLoS Negl Trop Dis; 2013; 7(3):e2124. PubMed ID: 23516657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delta inulin-derived adjuvants that elicit Th1 phenotype following vaccination reduces respiratory syncytial virus lung titers without a reduction in lung immunopathology.
    Wong TM; Petrovsky N; Bissel SJ; Wiley CA; Ross TM
    Hum Vaccin Immunother; 2016 Aug; 12(8):2096-2105. PubMed ID: 27215855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus.
    DeZure AD; Berkowitz NM; Graham BS; Ledgerwood JE
    J Infect Dis; 2016 Dec; 214(suppl 5):S497-S499. PubMed ID: 27920180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.